title: A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
abstract: Cisplatin and 5-fluorouracil act as radiosensitizers and are active cytotoxic drugs in head and neck cancer. Therefore, from May 1987 to June 1990, we gave a continuous course of radiotherapy (70 Gy/35 fractions/7 weeks) combined with the simultaneous administration, once a week, of cisplatin (40 mg/m2, i.v. bolus) and 5-fluorouracil (400 mg/m2, i.v. bolus) to 21 patients with locally advanced or recurrent tumors of the head and neck. The complete and partial response rates were 65% and 15%, respectively. With a median follow-up of 17 months (range: 4-42) and with 19/21 patients having stages III and IV tumors, 12 patients are NED (no evidence of disease), 8 died with tumor, and 1 died of bronchopneumonia during the treatment. The main toxicity was mucositis and the median length of therapy was higher than with irradiation alone. This regimen appears very encouraging and could be an improvement over radiation alone for patients with locally advanced head and neck cancer.
authors.affiliation: Department of Radiotherapy, General Hospital, Padova, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Tomio
authors.forename: P L
authors.initials: PL
authors.lastname: Zorat
authors.forename: A
authors.initials: A
authors.lastname: Paccagnella
authors.forename: R
authors.initials: R
authors.lastname: Segati
authors.forename: L
authors.initials: L
authors.lastname: Loreggian
authors.forename: O
authors.initials: O
authors.lastname: Lora
authors.forename: M L
authors.initials: ML
authors.lastname: Friso
authors.forename: V
authors.initials: V
authors.lastname: Chiarion-Sileni
authors.forename: A
authors.initials: A
authors.lastname: Favaretto
authors.forename: A
authors.initials: A
authors.lastname: Fede
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000145:classification; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa; D009305:Nasopharynx / Q000473:pathology; D009325:Nausea / Q000139:chemically induced / Q000145:classification; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010865:Pilot Projects; D011838:Radiation-Sensitizing Agents; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy / Q000009:adverse effects / Q000379:methods*; D013280:Stomatitis / Q000139:chemically induced / Q000145:classification; D014839:Vomiting / Q000139:chemically induced / Q000145:classification
chemical_list: D011838:Radiation-Sensitizing Agents; D002945:Cisplatin; D005472:Fluorouracil